Michael Nohaile
Director/Board Member chez FULGENT GENETICS, INC.
Fortune : 51 689 $ au 31/03/2024
Profil
Michael Nohaile is currently the Chief Executive Officer at Prellis Biologics, Inc. and an Independent Director at Fulgent Genetics, Inc. He is also the Chief Scientific Officer at Generate Biomedicines, Inc. Dr. Nohaile's former positions include Director at Genoptix, Inc., Senior VP-Strategy, Commercialization & Innovation at Amgen, Inc., General Manager-Molecular Diagnostics Business at Novartis Corp., and Partner at McKinsey & Co., Inc. Dr. Nohaile received his undergraduate degree from Massachusetts Institute of Technology and his doctorate from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FULGENT GENETICS, INC.
0,01% | 21/03/2024 | 2 382 ( 0,01% ) | 51 689 $ | 31/03/2024 |
Postes actifs de Michael Nohaile
| Sociétés | Poste | Début |
|---|---|---|
| FULGENT GENETICS, INC. | Director/Board Member | 01/08/2022 |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Chief Tech/Sci/R&D Officer | - |
Prellis Biologics, Inc.
 Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Chief Executive Officer | 11/08/2022 |
Anciens postes connus de Michael Nohaile
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/11/2012 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2007 |
Genoptix, Inc.
 Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Director/Board Member | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Formation de Michael Nohaile
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| FULGENT GENETICS, INC. | Health Services |
| Entreprise privées | 5 |
|---|---|
Genoptix, Inc.
Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Prellis Biologics, Inc.
Prellis Biologics, Inc. BiotechnologyHealth Technology Prellis Biologics, Inc. engages in building human tissues for drug development, and also develops human organs for transplantation. It offers vascularized tissue, bio and human organ printing. The firm's products include Organoid, Vascular Bundle, 3D Tissue Chip, Cell Seeding Matrix, Cell Adhesion Plus and Holograph-X Bioprinter. The company was founded by Noelle Huskey Mullin and Melanie Matheu in October 2016 and is headquartered in San Francisco, CA. | Health Technology |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Health Technology |
